Neutropenia

Latest News

4 Clinical Pearls for Granulocyte Colony Stimulating Factors (G-CSFs)

February 16th 2017

To help prevent and treat neutropenia, we routinely use Granulocyte Colony Stimulating Factors (G-CSF) for patients undergoing myelosuppressive chemotherapy.

Novartis Withdraws Drug Application for Biosimilar Zioxtenzo
Novartis Withdraws Drug Application for Biosimilar Zioxtenzo

February 2nd 2017

Granix by Teva Pharmaceuticals, Inc
Granix by Teva Pharmaceuticals, Inc

June 9th 2016

Clozapine Dispensing Requirements Changed
Clozapine Dispensing Requirements Changed

September 20th 2015

First Biosimilar Filgrastim Launched Today
First Biosimilar Filgrastim Launched Today

September 3rd 2015

Latest CME Events & Activities

Risks and Liabilities in Pharmacy Practice

1.0 Credit / Law

View More

Optimizing the Use of Targeted Therapies for the Treatment of ROS1-Rearranged and KRAS-Mutant Non−Small Cell Lung Cancer

1.0 Credits / Oncology

View More

An Article in the American Journal of Managed Care’s Evidence-Based Oncology: Navigating the Complexities of Frontline Immunotherapy in NSCLC

2 Credits / Oncology, Pulmonology/Respiratory

View More

Exploring the New Standard of Care for the Frontline Treatment of Non-Small Cell Lung Cancer: A Focus on Immunotherapy

1.5 Credits / Oncology, Pulmonology/Respiratory

View More

2022 ASH Annual Meeting Coverage—Recent Developments in Diffuse Large B-Cell Lymphoma: Insights and Application for Managed Care

1.0 Credit / Oncology

View More

CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care

1.5 Credits / Hematology, Oncology

View More

Evidence-Based Oncology: Discerning Novel Approaches, Recent Advances, and the Managed Care Considerations for Targeted Treatments in CLL

2.0 Credits / Hematology, Oncology

View More

Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia

1.5 Credits / Hematology, Oncology

View More

Evidence and Managed Care Considerations for the Use of Novel Immunotherapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

1.5 Credits / Oncology

View More

Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma

1.5 Credits / Hematology, Oncology

View More

New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes

1.5 Credits / Hematology, Oncology

View More

Translating Progress in BCMA-Directed Therapy for Multiple Myeloma into Advances in Patient Care

1.0 Credit / Hematology, Oncology

View More

Optimizing Outcomes for Older Patients With Acute Myeloid Leukemia: A Focus on Alternative Induction Regimens and Maintenance Therapy

1.0 Credit / Hematology, Oncology

View More

Enhancing the Safety of Outpatient CAR T-Cell Administration in Relapsed/Refractory Lymphomas Through Pharmacist-Directed Initiatives

1.0 Credit / Hematology, Oncology

View More

Ushering in a New Era of Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on New and Emerging Antibody-Based Regimens

1.0 Credit / Hematology, Oncology

View More

Treatment Strategies for Chronic Myeloid Leukemia and the Pharmacist’s Impactful Role

1.0 Credit / Hematology, Oncology

View More

Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based Regimens

1.0 Credit / Hematology, Oncology

View More

Optimizing Safe Use of Antibody-Drug Conjugates in Solid Tumors Through Pharmacist Interventions

1.0 Credit / Oncology

View More

Navigating Current and Emerging Treatment Options for Myelofibrosis After Frontline Failure

1.0 Credit / Oncology

View More

Optimizing Treatment of Early-Stage Breast Cancer and the Pharmacist’s Role in Managing Targeted Therapies

1.5 Credits / Oncology

View More

Targeted Therapies for Non-Small Cell Lung Cancer With ROS1 or KRAS Mutations and the Impact of Pharmacists’ Care

1.0 Credit / Oncology, Pulmonology/Respiratory

View More

Enhancing Care for Patients With Endometrial Cancer Through Pharmacist Interventions

1.0 Credit / Oncology, Women’s Health

View More

Investigating Novel Strategies for the Treatment of Metastatic Small Cell Lung Cancer After Frontline Treatment Failure

1.0 Credit / Oncology

View More

Clinical Updates and Strategies for Optimizing Use of Bispecific Antibodies in Hematologic Malignancies

1.0 Credit / Oncology

View More

Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies

1.5 Credits / Hematology, Oncology

View More

Perspectives on Emerging Data for the Use of Immunotherapy in the Treatment of Early-Stage Non-Small Cell Lung Cancer

1.5 Credits / Oncology, Pulmonology/Respiratory

View More

Promoting Adherence in Early-Stage HR+/HER2- Breast Cancer: The Value of Oncology Pharmacists in Preventing Premature Treatment Discontinuation

1.25 Credit(s) / Oncology; Women’s Health

View More

Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies

1.0 Credits / Hematology, Oncology

View More

Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team

1.5 Credits / Hematology, Oncology

View More

Advances in EGFR Exon 20 Insertion-Positive Non–Small Cell Lung Cancer: A Focus on Specialty Pharmacy Interventions

1.5 Credits / Oncology, Pulmonology/Respiratory

View More

© 2024 MJH Life Sciences

All rights reserved.